1800-272-662
Shopping Cart 0
countryflagAU
Login

Allergy Therapeutics

Healthcare GB AGY

11.35GBX
-0.15(1.30%)

Last update at 2026-03-11T10:37:00Z

Day Range

10.5511.50
LowHigh

52 Week Range

5.0012.10
LowHigh

Fundamentals

  • Previous Close 11.50
  • Market Cap675.56M
  • Volume8159
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-26.17700M
  • Revenue TTM55.04M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 29.30M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -40.44400M -39.16600M -49.82900M -12.65700M 3.66M
Minority interest - - - - -
Net income -40.13200M -40.21600M -51.02600M -13.77600M 2.89M
Selling general administrative 19.09M 22.79M 25.09M 20.83M 20.67M
Selling and marketing expenses 19.20M 19.59M 23.70M 26.00M 25.20M
Gross profit 25.13M 29.74M 34.61M 49.51M 62.23M
Reconciled depreciation 4.17M 4.32M 4.23M 4.17M 4.13M
Ebit -33.60100M -35.05900M -33.11900M -11.98800M 4.15M
Ebitda -29.42900M -30.74000M -28.89300M -7.82200M 8.28M
Depreciation and amortization 4.17M 4.32M 4.23M 4.17M 4.13M
Non operating income net other - - - - -
Operating income -29.50500M -35.25700M -36.12900M -12.24500M 4.03M
Other operating expenses 84.55M 90.46M 94.40M 85.01M 80.30M
Interest expense 6.84M 3.88M 2.75M 0.67M 0.49M
Tax provision 0.93M 1.05M 1.20M 1.12M 0.77M
Interest income 0.38M 0.28M 0.33M 0.26M 0.12M
Net interest income -6.78400M -3.90900M -2.42000M -0.41200M -0.37400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.31200M 1.05M 1.20M 1.12M 0.77M
Total revenue 55.04M 55.20M 60.95M 72.77M 84.33M
Total operating expenses 54.63M 64.99M 68.06M 61.75M 58.19M
Cost of revenue 29.91M 25.46M 26.34M 23.26M 22.11M
Total other income expense net -10.93900M -3.90900M -16.09800M -0.28400M -0.26900M
Discontinued operations - - - - -
Net income from continuing ops -40.13200M -40.21600M -51.02600M -13.77600M 2.89M
Net income applicable to common shares - - -51.02600M -13.77600M 2.89M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 67.54M 64.83M 68.40M 73.58M 88.09M
Intangible assets 0.93M 1.37M 1.05M 1.69M 1.41M
Earning assets - - - - -
Other current assets - - 10.47M 10.47M 6.75M
Total liab 95.74M 61.12M 73.18M 35.18M 39.55M
Total stockholder equity -28.19300M 3.71M -4.78300M 38.40M 48.53M
Deferred long term liab - - - - -
Other current liab 19.39M 9.68M 1.88M 13.77M 15.33M
Common stock 4.77M 4.78M 0.69M 0.64M 0.64M
Capital stock 4.77M 4.77M 0.69M 0.64M 0.64M
Retained earnings -195.09800M -198.92700M -168.71900M -117.91000M -107.39800M
Other liab - - 19.53M 8.87M 11.91M
Good will 3.33M 3.32M 3.35M 3.35M 3.34M
Other assets - - 5.81M 5.96M 5.76M
Cash 12.79M 12.91M 14.85M 20.52M 40.27M
Cash and equivalents - - - - -
Total current liabilities 27.19M 20.55M 19.06M 17.80M 18.23M
Current deferred revenue - 0.00000M -1.80300M -13.65500M -15.33300M
Net debt 47.50M 18.07M 21.55M -9.98600M -29.10100M
Short term debt 1.88M 2.12M 1.80M 2.02M 1.75M
Short long term debt 0.41M 0.60M 0.65M 0.95M 0.96M
Short long term debt total 60.09M 30.99M 36.40M 10.53M 11.17M
Other stockholder equity 154.65M 196.55M 163.25M 117.27M 106.76M
Property plant equipment - - 23.98M 20.19M 19.72M
Total current assets 34.68M 33.48M 34.21M 42.39M 57.86M
Long term investments - - - - -
Net tangible assets - - -9.18300M 33.36M 43.78M
Short term investments - 0.20M - - -
Net receivables 7.97M 7.82M 2.37M 5.91M 4.62M
Long term debt 53.04M 22.50M 26.85M 1.50M 2.45M
Inventory 13.91M 12.74M 11.59M 11.41M 10.84M
Accounts payable 4.49M 4.01M 17.17M 15.67M 16.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.50M 1.31M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.64M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.84M 2.91M -28.37700M -25.22500M -24.47100M
Deferred long term asset charges - - - - -
Non current assets total 32.87M 31.34M 34.19M 31.19M 30.23M
Capital lease obligations 6.64M 7.89M 8.90M 8.08M 7.76M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.27M -1.19900M -5.79200M -3.19800M -2.63900M
Change to liabilities - - 1.70M -1.87200M 0.55M
Total cashflows from investing activities -3.15500M -1.19900M -5.79200M -3.19800M -2.63900M
Net borrowings 34.68M 34.31M 24.45M -2.26800M -1.73700M
Total cash from financing activities 32.04M 31.43M 28.90M -2.63800M -2.03400M
Change to operating activities - - - - -
Net income -39.20000M -40.21600M -49.82900M -12.65700M 3.66M
Change in cash -0.12500M -1.93000M -5.67000M -19.75800M 3.31M
Begin period cash flow 12.91M 14.85M 20.52M 40.27M 36.96M
End period cash flow 12.79M 12.91M 14.85M 20.52M 40.27M
Total cash from operating activities -28.71700M -32.13800M -28.74500M -14.37200M 8.40M
Issuance of capital stock 0.00000M 2.42M 6.49M 0.00300M 0.00400M
Depreciation 4.17M 4.32M 4.23M 4.17M 4.13M
Other cashflows from investing activities - 0.14M -0.07700M 0.08M -0.07700M
Dividends paid - - - - -
Change to inventory -1.02000M -1.23900M -0.14200M -0.58600M -1.11700M
Change to account receivables 0.27M 0.14M 3.11M -4.24600M 2.14M
Sale purchase of stock - - - - 0.00400M
Other cashflows from financing activities -2.63600M -2.49700M 33.37M -1.68400M -1.28100M
Change to netincome - - 13.39M 1.58M -0.19100M
Capital expenditures 3.26M 3.40M 5.71M 3.28M 2.56M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.33400M -1.09500M 4.66M -6.34300M 1.57M
Stock based compensation 0.87M 0.76M 0.11M 0.47M 0.64M
Other non cash items 8.77M 4.85M 13.70M 0.41M 0.37M
Free cash flow -31.98100M -35.53900M -34.46000M -17.64800M 5.84M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGY
Allergy Therapeutics		 -0.15 1.30% 11.35 - 106.38 12.27 83.28 13.92 -4.1496
HLN
Haleon PLC		 -4.3 1.15% 368.70 24.73 16.86 2.63 1.81 3.17 16.57
HIK
Hikma Pharmaceuticals PLC		 17.00 1.42% 1214.00 33.45 11.14 1.45 2.32 1.76 8.98
HCM
HUTCHMED China Ltd		 1.00 0.47% 215.00 - - 3.22 3.97 2.39 -19.4252
ANCR
Animalcare Group Plc		 -1.0 0.37% 266.00 67.50 20.28 2.30 1.71 2.52 17.14

Reports Covered

Stock Research & News

View All

Profile

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Allergy Therapeutics

Dominion Way, Worthing, United Kingdom, BN14 8SA

Key Executives

Name Title Year Born
Mr. Manuel Llobet CEO & Exec. Director 1964
Mr. Martin Hopcroft Interim Chief Financial Officer NA
Ms. Beverly Lees Group Operations Director NA
Dr. Murray Skinner Chief Scientific Officer NA
Mr. Santiago Puig Bus. Devel. Director NA
Ms. Sue Baker Head of HR NA
Simon Piggott Head of Clinical Science NA
Alan Bullimore Head of Communication & Market Devel. NA
Mr. Russell Picket Group Financial Controller NA
Sara Goldsbrough Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.